Role of vasopressin and aldosterone in pulmonary arterial hypertension: A pilot study

Shweta Bansal, David Badesch, Todd Bull, Robert W. Schrier

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Much has been learned about the pathophysiological state that underlies the development of increased total body volume and edema in left ventricular failure. Very little, however, is known about the mechanism underlying systemic hypervolemia in patients with isolated right ventricular dysfunction. In this manuscript, we describe our randomized clinical trial to assess the relationship between severity of pulmonary arterial hypertension and neurohormonal activation, total plasma volume and renal function. We assess the role of aldosterone and vasopressin in volume retention in patients with pulmonary arterial hypertension with right ventricular failure. As understanding of the pathogenesis of left ventricular failure has been associated with improved therapies, the better understanding of the mechanisms of isolated right ventricular cardiac failure will also lead to improved patient care.

Original languageEnglish (US)
Pages (from-to)392-399
Number of pages8
JournalContemporary Clinical Trials
Issue number5
StatePublished - Sep 2009
Externally publishedYes


  • Aldosterone
  • Pulmonary arterial hypertension
  • Right ventricular failure
  • Spironolactone
  • Vasopressin

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Role of vasopressin and aldosterone in pulmonary arterial hypertension: A pilot study'. Together they form a unique fingerprint.

Cite this